REPL - Replimune Group, Inc.
IEX Last Trade
12.99
0.170 1.309%
Share volume: 18,753
Last Updated: Thu 26 Dec 2024 08:30:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$12.82
0.17
1.33%
Fundamental analysis
12%
Profitability
8%
Dept financing
4%
Liquidity
50%
Performance
10%
Performance
5 Days
1.30%
1 Month
-13.07%
3 Months
12.31%
6 Months
43.51%
1 Year
53.94%
2 Year
-52.87%
Key data
Stock price
$12.99
DAY RANGE
$12.37 - $12.86
52 WEEK RANGE
$5.08 - $17.00
52 WEEK CHANGE
$45.52
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Philip Astley-Sparke
Region: US
Website: replimune.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: replimune.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer.
Recent news